Adimmune Corp
TWSE:4142
Adimmune Corp
TWSE:4142
Price:
27.4 TWD
-2.49%
Market Closed
Updated:
May 13, 2024
Section:
Relative Value
The Relative Value of one
Adimmune Corp
stock under the Base Case scenario is
28.16
TWD.
Compared to the current market price of 27.4 TWD,
Adimmune Corp
is
Undervalued by 3%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
28.16
TWD
Undervaluation 3%
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Adimmune Corp Competitors
Adimmune Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| TW |
|
Adimmune Corp
TWSE:4142
|
11.5B TWD | 6.5 | -18 | -23.1 | -16 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.4B USD | 5.6 | 44.2 | 18.6 | 30.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.9B USD | 11 | 30.1 | 24.2 | 25.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.3B USD | 8.2 | 27.8 | 22.5 | 24.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.2B AUD | 6.3 | 36.1 | 21.8 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 169.8 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
44.9B USD | 8.7 | -7.5 | -8.1 | -7.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.3B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.2 | 73.8 | 45.6 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
